TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All individuals between 18-35 years of age~* Ability to understand study procedures and to comply with them~Exclusion Criteria:~* Non-English speakers~* Exclusion related to pregnancy, lactation, or has plans to become pregnant over the course of the study, Based on self-report from the participant~* Current scalp or hair disease diagnosis~* Using oral or topical antimicrobial medication 4 weeks prior to their baseline visit or in the duration of the study~* Current clinical condition that, in the opinion of the site investigator, would interfere with adherence to study requirements~* Inability or unwillingness of individual to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Healthy-experimental (Type: EXPERIMENTAL): Healthy participants who have not been diagnosed with scalp or hair disease will be followed over a period of 2 weeks to assess their scalp microbiome and see how well the investigational device works on decreasing the microbe burden of the scalp.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Measureable disease according to the RECIST 1.1~* Previous radiotherapy is acceptable provided there are measurable, previously not irradiated lesions present~* Histologically or cytologically confirmed non-squamous non-small cell lung cancer~* Stage IIIB ineligible for curative therapy or stage IV disease~* ECOG Performance 0-2~* Adequate organ function defined as:~  1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy.~ 2. Total serum bilirubin ≤ 1.5 x ULN~ 3. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~ 4. Platelets ≥ 100 x 109/L~ 5. Creatinine clearance \> 45 ml/min~* Able to discontinue NSAIDs and ASA if reduced renal function~* All fertile patients should use safe contraception~* Written informed consent~Exclusion Criteria:~* prior systemic therapy for advanced non-small-cell lung cancer (including EGFR-TKI). Previous chemotherapy (e.g. adjuvant after surgery or for other cancer) is allowed if ≥ 3 months since the last course was administered.~* activating EGFR-mutation or ALK-translocation detected~* serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study treatment~* conditions - medical, social, psychological - which could prevent adequate information and follow-up~* clinically active cancer other than NSCLC~* known hypersensitivity or contraindications for the study drugs (vinorelbine, carboplatin, pemetrexed, B12, folate)~* pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- maintenance pemetrexed (Type: EXPERIMENTAL): maintenance pemetrexed immediately after induction chemotherapy
- pemetrexed at progression (Type: ACTIVE_COMPARATOR): observation and pemetrexed therapy at disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients age ≥18 years~* Histologically confirmed primary (non-recurrent) adenocarcinoma (AC) or squamous cell carcinoma of the esophagus or AC of the gastroesophageal (GE) junction.~* For Phase 1: Phase 1 patients must have unresectable disease (Stage II to IVa). A patient can be unresectable for medical reasons or technical reasons but eligible for chemoradiation.~* For Phase 2: Phase 2 patients must have resectable cancer defined as: T2, T3, N0; OR T1-3, N+~* Patients must have archived tumor tissue to correlate tumor biomarker expression with clinical response. Availability of tumor specimens in paraffin blocks or at least two unstained slides must be confirmed prior to study entry. Results will not be used to determine patient eligibility for the study.~* ECOG performance status 0-1~* Adequate hematologic function~* Adequate liver and renal function~* Ability to swallow and retain oral medication.~Exclusion Criteria:~* Patients with distant metastasis, including M1b lymph node status. (M1b status allowed on Phase I only for patients appropriate for chemoradation). Lymph nodes suspicious of M1b status by diagnostic imaging must be verified by fine-needle aspiration cytology. (Phase 2 only)~* For Phase 2: Patients with positive pleural, pericardial, or peritoneal cytology.~* For Phase 2: Patients with carcinoma of the cervical esophagus.~* For Phase 2: Patients with clinical evidence of metastasis to cervical or supraclavicular lymph nodes.~* Prior chemotherapy or radiotherapy for esophageal or gastroesophageal junction cancer. Phase 1 patients with prior chemotherapy are permitted to enter.~* Prior radiotherapy that would overlap the anticipated study treatment fields or radiotherapy to \>30% of the marrow cavity (no prior chest irradiation).~* Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel are excluded. Subjects with ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction are also excluded.~* Pregnant or nursing females. Fertile patients (male and female) must use effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Therapy for Wasting in Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 18 years~* Cystic fibrosis, diagnosed by either sweat chloride or genetic testing~* Less than 92% ideal body weight based on body mass index (BMI) of 22 for women and 23 for men~* Moderate or better pulmonary function (Forced Expiratory Volume (FEV1) \>40% of predicted).~* Agree to use an effective method of birth control to prevent pregnancy during the research study.~Women should not nurse (breast feed) a baby while on this study because Nutropin AQ may enter breast milk and possibly harm the child.~Exclusion Criteria:~* Pregnancy (positive pregnancy test) prior enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation or trial~* Pediatric patients~* Active neoplasm~* History of organ transplantation~* Prader Willi Syndrome who are severely obese or have severe respiratory impairment~* Patients with hepatic impairment resulting in abnormal coagulation studies (\>1.5 times normal reference range)~* Poorly controlled diabetes as determined by a Hemoglobin A1c greater than or equal to 9.0%.~* Individuals with electrocardiogram abnormality or cardiac pacing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone Therapy (Type: EXPERIMENTAL): Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 11C-acetate for Treatment Response After Radiotherapy for HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Subject is willing to participate in the study and has signed the study informed consent~* Subject is available and willing to comply with the protocol evaluations~* Diagnosed hepatocellular carcinoma confined to a single lobe of the liver if undergoing 90Y radioembolization~* Diagnosed hepatocellular carcinoma confined to the liver if undergoing Stereotactic Body Radiation Therapy (SBRT)~* Under consideration for 90Y radioembolization or Stereotactic Body Radiation Therapy (SBRT)~Exclusion Criteria:~* Pregnant or planning to become pregnant within the next 12 months or breast-feeding~* GFR \< 45~* Life expectancy \< 6 months~* Claustrophobic and cannot tolerate imaging procedures~* Weigh \> 350 lb (upper weight limit of scanner beds)~* Special vulnerabilities (e.g. fetuses, neonatales, pregnant women, children, prisoners, institutionalized individuals).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy treatment monitoring of hepatocellular carcinoma (Type: OTHER): All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exploration of Ejaculation Changing Mechanism After Surgery for Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man, at least 18 years, which is scheduled for a BPH surgery~* Sexually active~* Measurement of Residual postvoid less than 6 months~* Patients accepting the constraints of the study~* Signed Consent~* Affiliate or beneficiary of social security system.~Exclusion Criteria:~* Patients unable to understand the study or to give consent~* Patients with known infertility~* Patients previously operated prostate~* Patients previously treated with a natural prostate treatment (radiotherapy, microwave, radio frequency, ultrasound)~* Patients with known urethral stenosis before surgery~* Patient with impaired preoperative in ejaculation~* Patient under guardianship or under judicial protection~* Patient subject to psychiatric care

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Search retrograde ejaculation (Type: EXPERIMENTAL): Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Resistance STEMI Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years~* Presentation within 12 hours after the onset of complaints~* Acute ST-elevation myocardial infarction with a total ST segment deviation ≥5 mm~* Able to give and understand informed consent~* Culprit lesion in a proximal or mid-segment of one of the major coronary arteries (diameter ≥2,5 mm), which is stented successfully~* Stable condition after stenting~* One or more additional lesions in one or more different coronary arteries, mandating FFR measurement +/- PPCI during the subacute phase~Exclusion Criteria:~* Age \< 18 years or \> 75 years~* Cardiogenic shock or pre-shock, determined by the clinician~* Patients with previous myocardial infarction in the culprit artery or with previous bypass surgery~* Very tortuous or calcified coronary arteries~* Long or complex PPCI~* Severe concomitant disease or conditions with a life expectancy of less than 1 year~* Inability to understand and give informed consent~* Known myocardial diseases such as severe left ventricular hypertrophy or cardiomyopathy~* Pregnancy~* Severe conduction disturbances necessitating implantation of a temporary pacemaker~* Contraindications for MRI (claustrophobia, ferromagnetic metal fragments in the body)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study arm (Type: OTHER): The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of chronic myelogenous leukemia (CML) documented by cytogenetic and molecular analyses at Johns Hopkins~  * Philadelphia chromosome (Ph)-positive or -negative CML~    * Ph-negative CML allowed with presence of either:~      * BCR-ABL rearrangement (on molecular, fluorescent in situ hybridization, or polymerase chain reaction analyses)~     * p210 protein~* One of the following:~  * Patient age 18 to 65~ * Disease duration longer than 3 years~ * Accelerated phase CML~* Accelerated phase diagnosis based on any of the following:~  * More than 10% to less than 30% blasts in blood or bone marrow~ * No hematologic response to prior conventional therapy (hydroxyurea or interferon)~ * Extramedullary disease (e.g., progressive splenomegaly or lymphadenopathy)~ * Basophilia greater than 10% in blood or bone marrow~ * Other cytogenetic abnormalities in addition to a single Ph chromosome~ * Second chronic phase~* Failure on interferon suggested of patients over age 18 with chronic phase CML, with failure defined as:~  * No detectable Ph-negative metaphases in marrow after 6 months~ * No progressive increase in Ph-negative metaphases in marrow after 6-12 months~ * Less than 50% Ph-negative metaphases after 1 year~ * No complete cytogenetic remission after 2 years~ * Intolerance to interferon therapy~* No blast crisis CML, chronic myelomonocytic leukemia, or juvenile CML~* The following conditions are allowed:~  * Leukocyte count abnormalities~ * Fibrosis~ * Anemia~ * Fever or bone pain~ * Thrombocytopenia~ * Bone marrow reticulin~* Availability of an HLA-identical sibling donor~  * At least 3 years of age (priority given to donors over age 10)~ * Priority given to CMV-negative donor if patient CMV-negative~ * No medical or psychiatric condition that precludes transplant procedure~PATIENT CHARACTERISTICS:~Age~* 18 to 65~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Not specified~Renal~* Not specified~Other~* No history of intolerance to sargramostim (GM-CSF)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent (for the intervention arm only)~* No prior history of confirmed COVID-19 (i.e., based on a positive FDA-approved assay for SARS-CoV-2 and no documented FDA-approved serological test results for antibodies to SARS-CoV-2 found in health system databases)~* Established ASCVD (i.e., defined as prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, ischemic stroke, and/or peripheral artery disease)~* At least 12 months of continuous health plan membership and prescription drug benefit prior to enrollment~* A registered e-mail address with the health care delivery system in order to facilitate obtaining electronic consent for study participation~Exclusion Criteria:~* Receipt of IPE on or within 12 months before the day of enrollment~* Known hypersensitivity to IPE, fish, and/or shellfish~* Documented use of any omega-3 fatty acid medications or dietary supplements containing omega-3 fatty acids in the EHR~* Women who are pregnant or planning to become pregnant~* Hospitalization for myocardial infarction and/or elective percutaneous coronary intervention within the past 1 month~* Currently receiving triple anti-thrombotic therapy~* Stage D heart failure~* Severe liver disease~* End-stage renal disease requiring chronic dialysis or estimated glomerular filtration rate \<15 mL/min/1.73 m2~* Metastatic cancer and/or receiving active systemic chemotherapy~* Institutionalized and/or receiving palliative care

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): None
- Usual Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Hong Kong and Taiwan HM3 PMS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- All patients at the participating sites that are determined to meet the HM3 commercially approved labelling indication and have a planned HM3 implant are eligible to participate in this PMS. Assessment for eligibility criteria is based on medical records of the site and interview with a candidate patient.~Exclusion Criteria: None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HeartMate 3™ left ventricular assist system (HM3 LVAS) (Type: EXPERIMENTAL): Patients will be implanted with the HM3 LVAS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MultiPoint Pacing Mapping Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be scheduled to undergo or have received within the past 30 days an implant of a SJM (St. Jude Medical) MPP CRT-D system with approved standard indication by ESC (European Society of Cardiology) / EHRA (European Heart Rhythm Association) Guidelines~* Have the ability to provide informed consent for study participation and be willing and able to comply with the Clinical Investigation Plan (CIP) described evaluations and follow-up schedule~* Be in sinus rhythm~Exclusion Criteria:~* Complete AV (atrioventricular) block~* Permanent atrial fibrillation~* Have a recent myocardial infarction within 40 days prior to enrollment~* Have undergone cardiac surgery or coronary revascularization procedure within 3 months prior to enrollment or be scheduled for such procedures in the following 7 months~* Have had a recent CVA (cerebrovascular accident) or TIA (transient ischemic attack) within 3 months prior to enrollment~* Have had intravenous inotropic support in the last 30 days~* Be less than 18 years of age~* Be pregnant or plan to become pregnant over the next 7 months~* Have significant peripheral vascular disease~* Have LV thrombus~* Significant aortic valve disease or replacement~* Mitral valvular disease~* Contraindicated for Gadolinium contrast agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues